Psoriasis: response to high-dose intravenous immunoglobulin in three patients

Gurmin, V; Mediwake, Rapti; Fernando, Maria Michelle; Whittaker, Sean; Rustin, M.H.A.; Beynon, HL

doi:10.1046/j.1365-2133.2002.04753.x

Cited by 37 publications

(18 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Bazı yazarlar bu temelden yola çıkarak IVIG tedavisinin psoriaziste uygulanabileceğini öne sürmüşlerdir. IVIG'in, TNF-α gibi sitokinlerin oluşumunu inhibe ederek psoriaziste uygulanabileceği öne sürülmüştür [6][7][8][9][10][11][12][13][14][15] . Gebelikte de çeşitli otoimmun hastalıklarda güvenle kullanılabilmesi ve iyi tolere edilmesi sebebiyle de teratojenik olmadığı bilinmektedir 7 .…”

Section: Discussionunclassified

Tedaviye Dirençli İmpetigo Herpetiformis'te İntravenöz İmmunglobulin Tedavisinin Etkinliği: Olgu Sunumu

...

2012

Turkderm

View full text Add to dashboard Cite

Özetİmpetigo herpetiformis (İH), yüksek fetal morbidite ve mortaliteye sahip, bazen gebeliğin sonlandırılmasını gerektirebilen bir hastalıktır. Etkili olduğu belirtilen farklı tedavi seçenekleri bulunmaktadır. Yirmi üç yaşında, psoriazis öyküsü olan 25 haftalık gebe olgu, ani başlangıçlı jeneralize püstüler döküntülerle başvurdu. Klinik bulgular ve histopatolojik değerlendirme ile İH tanısı konuldu. Sistemik prednizolon (2 mg/kg/gün) üç hafta süreyle uygulandı. Yanıt olmadığı için siklosporin A (3mg/kg/gün) ilave edildi. İki hafta siklosporin A ve sistemik prednizolon kombine kullanılmasına rağmen deri bulguları gerilemedi. Tedavilere ek olarak 30. Sum maryImpetigo herpetiformis (IH), if left untreated, is associated with a high rate of perinatal morbidity and mortality and may lead to the decision of termination of pregnancy. There are various and effective therapeutic agents available for the treatment of the disease. A 23-year-old woman with a history of plaque psoriasis presented with a sudden generalized pustular eruption on the 25th week of her first gestation. The diagnosis was made based on the clinical and histopathological findings. The patient was treated with systemic prednisolone (2 mg/kg/d) first and, cyclosporine A (3 mg/kg/d) was added to the treatment after two weeks because prednisolone was not effective alone. The lesions did not regress despite four weeks of combined treatment with prednisolone and cyclosporine. Intravenous immunoglobuline (IVIG) (0.3 g/kg/d, 6 days) was added on the 30th week of gestation and resulted in regression of cutaneous rashes. On the 33rd week of gestation, IVIG (0.7 g/kg/d, 3 days) was repeated due to reactivation of pustules, and an improvement was observed. In this case report, we called attention to IVIG therapy in IH, for having the pregnancy continued enough for the fetal maturation before the delivery. (Turk derm 2012; 46: 104-6

show abstract

Section: Discussionunclassified

Tedaviye Dirençli İmpetigo Herpetiformis'te İntravenöz İmmunglobulin Tedavisinin Etkinliği: Olgu Sunumu

...

2012

Turkderm

View full text Add to dashboard Cite

show abstract

“…Even though we observed a decrease in virus load, IVIG treatment was not sufficient to improve significantly the clinical course in our two cases of long-lasting rheumatic diseases. This seems not to be a general feature of psoriatic arthritis, because Gurmin and colleagues report three patients with improvement of their arthritis after a single course of IVIG (2 g/kg body weight) [16]. …”

Section: Discussionmentioning

confidence: 99%

Intravenous immunoglobulin treatment of four patients with juvenile polyarticular arthritis associated with persistent parvovirus B19 infection and antiphospholipid antibodies

et al. 2003

View full text Add to dashboard Cite

Parvovirus B19 infection has been associated with a wide spectrum of diseases. Besides acute infection resulting in anaemia and erythema infectiosum (fifth disease), a rash illness of childhood, hydrops fetalis in pregnant women and acute symmetrical polyarthropathy in adults have been reported as clinical manifestations. Depending on the haematological status of the host, B19 infection can be associated with haematopoietic disorders such as antiplastic crisis, thrombocytopenia and pancytopenia. Hepatitis, myocarditis, myositis, neurological disease and vasculitis can occur occasionally [1]. The relation of the infection to acute arthritis-arthralgias in children is well known. Some of the affected children develop chronic arthritis that is indistinguishable from juvenile idiopathic arthritis [2][3][4][5]. In these patients parvovirus B19 could ANA = anti-nuclear antibodies; anti-PL IgG = antiphospholipid antibodies; β 2 GPI = β 2 -glycoprotein I; CK = creatine kinase; CRP = C-reactive protein; ENA = extractable nuclear antigens; ESR = erythrocyte sedimentation rate; IVIG = intravenous immunoglobulin; KINDL = Health-related Quality of Life Questionnaire for Children; MTX = methotrexate; NSAID = non-steroidal anti-inflammatory drugs; TCHA = triamcinolone hexaacetonid; VP1 = viral protein 1; VP2 = viral protein 2. Online ISSN 1478-6362). This is an Open Access article: verbatim copying and redistribution of this article are permitted in all media for any purpose, provided this notice is preserved along with the article's original URL. AbstractChildren with rheumatic oligoarthritis and polyarthritis frequently establish persistent parvovirus B19 infections that may be associated with the production of antiphospholipid antibodies (anti-PL IgG). In this study we analysed the influence of high-dose intravenous immunoglobulin (IVIG) therapy on virus load, on the level of anti-PL IgG and its potential capacity to improve the patients' clinical status. Four juvenile patients with long-lasting polyarticular rheumatic diseases and persistent parvovirus B19 infection, associated in three cases with the presence of antibodies against β 2 -glycoprotein I (anti-β 2 GPI IgG), were treated with two cycles of IVIG on five successive days (0.4 g/kg per day). Clinical parameters including scores of disease activity, virus load and anti-PL IgG levels were determined before, during and after treatment. Two patients showed a complete remission that has lasted 15 months. During that period they showed neither clinical nor laboratory signs of inflammation. Viral DNA was not detectable in serum, and a decrease in anti-β 2 GPI IgG was observed. As assessed by the Childhood Health Assessment Questionnaire and the Health-related Quality of Life Questionnaire for Children, both patients were no longer restricted in their activities of daily living and no impact on the health-related quality of life was observed. In one patient the therapy failed: there was no improvement of symptoms and no decrease in virus load or inflammatory parameters. ...

show abstract

“…The patients were administered IVIG 2/kg over 3-4 days. Skin lesions improved dramatically in 2 patients and became less severe in the other patient [93].…”

Section: Psoriasismentioning

confidence: 97%

Intravenous Immunoglobulin Therapy in Dermatologic Disorders

Çakmak¹,

Gül²,

Gönül³

et al. 2008

IADT

View full text Add to dashboard Cite

Intravenous immunoglobulin (IVIG) is sterilized and purified human plasma which contains supra-physiologic levels of immunoglobulin G. IVIG is currently used in the treatment of immunodeficiency syndromes, inflammatory disorders and infectious diseases. Although numerous immunomodulatory mechanisms have been suggested, the exact mechanisms of action are poorly understood. There is also accumulating evidence that high-dose IVIG is efficacious in the treatment of some skin diseases, despite the lack of evidence from randomized, double-blind, placebo-controlled trials. Though in most cases, IVIG is only effective in combination with other immunomodulating strategies, it offers new hope for the treatment of many severe dermatologic conditions. This article focuses on the efficacy and safety of IVIG therapy in skin diseases.

show abstract

Psoriasis: response to high-dose intravenous immunoglobulin in three patients

Cited by 37 publications

References 33 publications

Tedaviye Dirençli İmpetigo Herpetiformis'te İntravenöz İmmunglobulin Tedavisinin Etkinliği: Olgu Sunumu

Tedaviye Dirençli İmpetigo Herpetiformis'te İntravenöz İmmunglobulin Tedavisinin Etkinliği: Olgu Sunumu

Intravenous immunoglobulin treatment of four patients with juvenile polyarticular arthritis associated with persistent parvovirus B19 infection and antiphospholipid antibodies

Intravenous Immunoglobulin Therapy in Dermatologic Disorders

Contact Info

Product

Resources

About